Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer. Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.
Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.
Manna Research, Toronto, Ontario, Canada
Georgina Family Medical Centre, Keswick, Ontario, Canada
Aggarwal and Associates Ltd, Brampton, Ontario, Canada
Research Site, Poltava, Ukraine
Asan Medical Center, Seoul, Korea, Republic of
Samsung Medical Center, Seoul, Korea, Republic of
Inje University Paik Hospital, Goyang, Korea, Republic of
Kangwon National University Hospital, Chuncheon, Gangwon, Korea, Republic of
Kwandong University College of Medicine Myongji Hospital, Gyeonggi-do, Goyang, Korea, Republic of
Dong-A University Hospital, Busan, Korea, Republic of
Omaha Veterans Affairs Medical Center, Omaha, Nebraska, United States
Medical University of Vienna, Dept. of Psychiatry and Psychotherapy, Vienna, Austria
Weill Medical College of Cornell University, New York, New York, United States
Centre de Thérapies Breves (CTB), Secteur Jonction, Geneva, Switzerland
Forest Investigative Site 017, Atlanta, Georgia, United States
Forest Investigative Site 010, Dallas, Texas, United States
Forest Investigative Site 013, Jacksonville Beach, Florida, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.